GlassScriptPhysician profile
Kumutha F Daniel
NPI 1225627136
$3,305.54
in general payments reported to CMS, 2019-2025
21 companies · $1,862 in 2025
The $1,862 reported for 2025 was more than what 91% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $21.90 · 2022: $369 · 2023: $305 · 2024: $748 · 2025: $1,862.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,803 · Education: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,803.18 |
| Education | $111.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $520.01 | 2021-2025 | Fanapt, Hetlioz |
| Abbvie INC. | $429.85 | 2023-2025 | |
| Alkermes, INC. | $386.66 | 2022-2025 | Aristada, Lybalvi, Vivitrol |
| Janssen Pharmaceuticals, INC | $386.47 | 2024-2025 | Invega Sustenna, Invega Trinza, Spravato |
| Lundbeck LLC | $355.93 | 2022-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Otsuka America Pharmaceutical, INC. | $318.94 | 2022-2025 | Abilify Asimtufii, Abilify Maintena, Rexulti |
| Teva Pharmaceuticals USA, INC. | $281.48 | 2024-2025 | Uzedy, Austedo Xr |
| E.R. Squibb & Sons, L.L.C. | $115.71 | 2024-2025 | Cobenfy |
| Neurocrine Biosciences, INC. | $96.42 | 2025 | |
| Axsome Therapeutics, INC. | $88.67 | 2023-2025 | Auvelity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $65.33 | 2025 | Caplyta |
| Corium, LLC | $48.71 | 2024 | Azstarys |
| Novo Nordisk INC | $42.02 | 2025 | Wegovy |
| Luye Pharma (USA) LTD. | $39.47 | 2025 | Erzofri Extended-Release |
| Indivior INC. | $29.10 | 2023-2024 | Perseris |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka Pharmaceutical Development & Commercialization, INC. | $23.41 | 2025 | |
| Noven Therapeutics, LLC | $17.65 | 2022 | |
| Supernus Pharmaceuticals, INC. | $17.34 | 2025 | Qelbree |
| Idorsia Pharmaceuticals US INC | $14.83 | 2023 | Quviviq |
| Tms Neurohealth Centers INC. | $14.00 | 2025 | Tms Neurohealth Centers INC. |
| Almatica Pharma LLC | $13.54 | 2025 | Loreev Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kumutha Daniel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.